News

Cambrex Announces Completion of Acquisition by the Permira Funds

04 December 2019

Cambrex Corporation (NYSE: CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced the completion of its previously announced sale to an affiliate of the Permira funds.

The Permira funds’ investment will support the ongoing growth of Cambrex’s integrated services offering by enhancing the company’s ability to service its global customer base, and broadening its capabilities to provide additional world class services to support the analysis, development and manufacturing – from preclinical through commercial phases – of drug substances and products.

“The completion of this transaction kicks off the next exciting phase of growth for our company,” commented Steve Klosk, President and CEO of Cambrex.  “We look forward to working with the Permira team to further enhance our best-in-class capabilities, strengthen our market-leading position, and broaden and deepen our customer relationships.”

Cambrex today also announced the appointment of Wayne Hewett as Chairman of the Board of Directors.  Mr. Hewett is a seasoned industry executive with deep operational and leadership experience across multiple industries. He currently serves as the Chairman of DiversiTech, a Permira portfolio company, and is a board member of Wells Fargo and The Home Depot.

Media contacts

Nina Suter Head of Communications - Director +44 (0) 207 632 4037